YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

Merck inks $11B acquisition

Posted online

Merck announced plans to buy Prometheus Biosciences.

The deal is valued at $10.8 billion.

Prometheus Biosciences has an experimental treatment for ulcerative colitis and Crohn's disease, according to CNBC.

Read more from CNBC.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
Fall 2026 Architects & Engineers Project Report

This installment of Springfield Business Journal’s Architects & Engineers Project Report showcases 26 endeavors by area design and engineering professionals.

Most Read
Update cookies preferences